Marisa Wexler, MS,  senior science writer—

Rystiggo (rozanolixizumab-noli) can be safely self-administered by people with myasthenia gravis (MG), according to data from a Phase 3 clinical trial. Based on these findings, at-home administration of Rystiggo was authorized earlier in 2025 in Japan and Europe. The work was funded by UCB, the company that sells Rystiggo.

A European Medicines Agency (EMA) committee recommended that the agency approve nipocalimab as an add-on treatment for generalized myasthenia gravis (gMG) patients aged 12 and older who have antibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). The Committee for Medicinal Products for Human Use (CHMP) recommendation comes a…

Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are generally safe and effective for easing symptoms of generalized myasthenia gravis (gMG) when used in everyday clinical practice. That’s according to data from the MG SPOTLIGHT Registry (NCT04202341), which was established to assess the long-term effectiveness of both therapies in…

Treatment with the experimental injection therapy claseprubart (DNTH103) was well tolerated and appeared to ease symptoms of generalized myasthenia gravis (gMG) in a Phase 2 clinical trial involving people with the autoimmune neuromuscular condition. That’s according to top-line data announced by the therapy’s developer Dianthus Therapeutics. The…

A new Phase 3 clinical trial testing Kyverna Therapeutics’ cell therapy candidate KYV-101 in people with myasthenia gravis (MG) — a study the developer says “supports [a] clear and rapid path to [regulatory approval]” — is expected to start enrolling participants before the end of the year, according to…

Two genes that help to control the human body’s biological clock are dysregulated in myasthenia gravis (MG) — a disease marked by symptoms that often grow worse throughout the day — according to the findings of a new study from China. Study data indicated that dysregulation of these genes,…

Treatment with gefurulimab, an experimental self-administered injection therapy, outperformed a placebo in easing symptoms of generalized myasthenia gravis (gMG) among people with the chronic autoimmune disease, the results of a Phase 3 clinical trial show. The trial met both its primary and secondary endpoints, or goals, with treatment…

Remegen’s telitacicept has been approved in China as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — that’s approximately 80% of all gMG patients, per the company. The decision, by the country’s National Medical Products Administration…

A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly 30 out of every 1 million children in the U.S., and may be more common than previously thought, a study estimates. The study also found that JMG is more common…

Kyverna Therapeutics is planning to launch a Phase 3 clinical trial testing its experimental cell therapy KYV-101 in people with myasthenia gravis (MG). The announcement follows an end-of-Phase 2 meeting between Kyverna and the U.S. Food and Drug Administration (FDA). According to the company, the FDA has…